Researchers at ebbu are using human clinical studies to track and record how different strains affect different patients to help users find the cannabis product they want and need.
The market for cannabis and hemp products has seen a low-key but potentially huge step forward in recent weeks.
The Palm Desert facility will offer comprehensive compliance testing services in addition to research and development into new cannabis products.
An Australian study of medicinal cannabis used to treat childhood epilepsy has found most samples contained some THC and little CBD, contrary to parents' expectations.
A four-year study suggests medicinal cannabis is not as effective at relieving chronic non-cancer pain as commonly assumed.
While cannabis hasn’t been shown to cure cancer on its own, despite the pervasiveness of anecdotal stories, scientists have found that cannabinoids have anti-cancer properties that could be helpful in drug development.
A majority of Australian GPs support medicinal cannabis being available on prescription, with their preferred "access model" involving trained GPs prescribing independently of specialists.
In 2013, UCSF Benioff Children’s Hospital San Francisco became the first site to administer the drug in a child, and as of this week, the FDA has approved its use in two rare and devastating forms of epilepsy.
The lab will run full-service testing for cannabinoid profiles, terpenes, pesticides, heavy metals, biological screening, and residual solvents, testing for 10+ cannabinoids and 40+ terpenes.
While medical marijuana supporters may cite the FDA approval of Epidiolex as evidence of the benefits of marijuana, it is not an endorsement of any CBD or cannabis product.